For research use only. Not for human or veterinary use. 21+.
Buy one, get one freeOn every vial · no code neededShop the offer
MANUFACTURED & SHIPPED FROM THE USA
Tesamorelin 10 mg — Peptides Only, research use only
Peptides · GH Axis

Tesamorelin

99.93% purity · Lot AV2C30 · tested May 12, 2026
CAS218949-48-5FormulaC221H366N72O67SMW5135.86

Stabilised GHRH analogue used in visceral-adiposity research.

  • Independently tested
  • Lot-matched COA
  • Lyophilized for stability
  • Ships from the USA
Research use only. Not for human or veterinary use. Sold to qualified researchers aged 21+.
$140.002 for $140 — $70 per vial
Buy one, get one free. Mix and match any 2 eligible vials and the lower-priced one is free — applied automatically. One-time purchases only.
1
Tesamorelin$140.002 for $140
Lot-matched documentation. Every order ships with the certificate for its lot. If a vial arrives damaged or doesn't match its paperwork, tell us within 72 hours and we'll replace it.

Latest lab results

Third-party tested

Tesamorelin 10 mg

Purity (HPLC-UV)
99.93%
Identity (LC-MS)
Confirmed — Tesamorelin
Net content
11.08 mg (label 10 mg)
Lot
AV2C30
Tested
May 12, 2026
Lab
Freedom Diagnostics Testing
View certificate (PDF)

Your order ships with the certificate for its own lot. 1 earlier certificate for this size in the COA library.

About Tesamorelin

Stabilised GHRH analogue used in visceral-adiposity research.

Supplied as

10 mg per vial, as a lyophilized powder in a sealed glass vial with a crimped cap. The lot number on the label matches the certificate of analysis in the COA library.

Storage and handling

Store lyophilized powder frozen (−20 °C) or refrigerated, sealed and away from light. Once reconstituted, keep refrigerated (2–8 °C).

Handle in a laboratory setting using appropriate protective equipment. Consult the certificate of analysis and safety data for lot-specific information.

Important research notice. This product is intended solely for in-vitro and laboratory research. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be used in humans or animals. Peptides Only does not provide usage or dosing information.

Research summary

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoyl group attached to its N-terminal tyrosine, a change that protects it from enzymatic breakdown. It is the active ingredient of an FDA-approved medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and one of the most closely studied GHRH analogs in visceral-fat, liver-fat and GH-axis research. The research-grade peptide sold here is a laboratory reagent, not that medicine.

Also known as
TH9507 · TH-9507 · trans-3-hexenoyl-hGRF(1-44)-NH2
Sequence
(trans-3-Hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

What is tesamorelin?

Tesamorelin (development code TH9507) is built on the full 44-residue sequence of human GHRH, the hormone whose structure was first worked out in the early 1980s from a human pancreatic tumor that had caused acromegaly1. The only change is a trans-3-hexenoyl group on Tyr1. In non-clinical studies that modification made the peptide resistant to dipeptidyl aminopeptidase-IV (DPP-IV), slowed its degradation in rat, dog and human plasma, prolonged its elimination, and produced marked rises in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in pigs, rats and dogs2.

As a GHRH analog, tesamorelin prompts the pituitary to release endogenous GH rather than supplying GH itself; in the pivotal phase 3 trial, circulating IGF-1 rose by 81% with tesamorelin and fell by 5% with placebo3. That makes it a different tool from ghrelin-receptor agonists such as ipamorelin, which reach the same pituitary cells through a separate receptor. The two classes are compared in Ipamorelin vs Sermorelin vs Tesamorelin.

Is tesamorelin FDA-approved? A medicine and a research peptide

Tesamorelin is the active ingredient of Egrifta, first approved by the US Food and Drug Administration in 2010 and now marketed as Egrifta SV and Egrifta WR. The current label indicates it for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, notes that long-term cardiovascular safety has not been established, and states that it is not indicated for weight-loss management.

That approval covers only the finished prescription medicine made and tested under its FDA application. Research-grade tesamorelin, including the material sold here, is a laboratory reagent: it is not a drug, it is not for human or veterinary use, and nothing on this page describes how it might be used in people.

What the pivotal HIV trials found

The anchor study is the 2007 phase 3 trial by Falutz and colleagues in the New England Journal of Medicine. Among 412 people with HIV and abdominal fat accumulation randomized to tesamorelin or placebo for 26 weeks, visceral adipose tissue measured by CT fell by 15.2% with tesamorelin and rose by 5.0% with placebo; triglycerides and the total-to-HDL cholesterol ratio also fell, and glycemic measures did not differ between groups. More participants withdrew from the tesamorelin arm because of adverse events3.

A pooled analysis of two phase 3 trials with 806 participants reported a placebo-adjusted visceral-fat effect of about -15%, no significant change in abdominal fat beneath the skin, and maintenance of the visceral-fat reduction to week 52 in participants who continued4. A 2026 meta-analysis of five randomized trials reported reductions in visceral, trunk and hepatic fat, an increase in lean mass, and no significant change in fat beneath the skin or in BMI5.

Newer research: liver fat and cognition

  • Liver fat: in a 50-person randomized trial, six months of tesamorelin was associated with reductions in visceral fat and modest reductions in liver fat versus placebo; fasting glucose rose at two weeks but the difference was not significant at six months6.
  • Fatty liver disease in HIV: a 61-participant multicenter trial reported a 37% relative reduction in hepatic fat fraction over 12 months versus placebo, with no between-group difference in fasting glucose or HbA1c7.
  • Cognition: in a controlled trial of 152 older adults with or without mild cognitive impairment, 20 weeks of tesamorelin was associated with a favorable effect on executive-function measures8, whereas a 2025 open-label phase 2 trial in people with HIV found no significant between-group difference in neurocognitive performance9.

Limitations of the evidence

Almost all human data on tesamorelin come from adults with HIV and central fat accumulation, so the findings do not automatically extend to other populations. Randomized, placebo-controlled phases lasted from 20 weeks to 12 months7,8, the cognitive results differ between populations8,9, and in dogs prolonged exposure to supraphysiological GH and IGF-1 was linked to reversible liver, kidney and blood findings2.

None of these studies used research-grade material, whose identity and purity have to be confirmed lot by lot. Every Peptides Only lot ships with a lot-matched certificate of analysis (HPLC purity and mass-spec identity) from an independent lab, published in the COA library.

Tesamorelin FAQ

Is tesamorelin approved by the FDA?

Tesamorelin is the active ingredient of an FDA-approved prescription medicine, Egrifta, first approved in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Research-grade tesamorelin is not that medicine and is not approved for any human use.

What is the difference between tesamorelin and sermorelin?

Both are GHRH analogs. Sermorelin is the 29-residue N-terminal fragment of GHRH, described as the shortest synthetic peptide with full GHRH activity10. Tesamorelin keeps all 44 residues and adds an N-terminal hexenoyl group that resists DPP-IV breakdown2.

Does tesamorelin raise IGF-1?

In the 26-week phase 3 trial, IGF-1 rose by 81% in the tesamorelin group and fell by 5% with placebo3; the pooled phase 3 analysis also reported a significant IGF-1 increase versus placebo4.

Why is tesamorelin studied in liver-fat research?

Because visceral fat and liver fat travel together in HIV-associated metabolic disease, and randomized trials reported reductions in hepatic fat alongside visceral fat6,7. Long-term effects on liver histology remain unknown.

How is lyophilized tesamorelin stored?

Like most lyophilized peptides it is generally kept sealed, cold, dry and away from light. Our guide to peptide storage and stability covers the general principles; Peptides Only gives no usage information.

Further reading

References

  1. Esch FS, Böhlen P, et al. Primary structures of three human pancreas peptides with growth hormone-releasing activity. J Biol Chem. 1983;258(3):1806-12. PubMed 6130096
  2. Ferdinandi ES, Brazeau P, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611
  3. Falutz J, Allas S, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338
  4. Falutz J, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713
  5. Badran AS, Helal A, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PubMed 41545261
  6. Stanley TL, Feldpausch MN, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PubMed 25038357
  7. Stanley TL, Fourman LT, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038
  8. Baker LD, Barsness SM, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PubMed 22869065
  9. Ellis RJ, Vaida F, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. PubMed 39813152
  10. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. PubMed 18031173

Research summary reviewed 2026-10-26 against the cited literature.

More Peptides

You might also need

View all
GHK-Cu 50 mg — Peptides Only, research use onlyBestsellerBuy One Get One
Lyophilized vial

GHK-Cu

Copper-binding tripeptide used in collagen and skin-matrix research.

$50.00
2 for $50 · $25/vial
NAD+ 100 mg — Peptides Only, research use onlyBestsellerBuy One Get One
Lyophilized vial

NAD+

Essential coenzyme for studies of cellular metabolism and ageing.

$50.00
2 for $50 · $25/vial

Contact Peptides Only

Operated by DND Wellness LLC · 1309 Coffeen Ave, Suite 1200, Sheridan, WY 82801.

support@peptides-only.com · (508) 404-8124

Use the chat widget to ask a question. Informational and promotional text messages require separate, optional consent. Message frequency varies. Msg & data rates may apply. Reply STOP to unsubscribe or HELP for help. Consent is not a condition of purchase. 21+.

SMS consent & support · SMS terms & Terms of Service · Privacy Policy